4M BioTech

4M Therapeutics is a private early-stage biotechnology company developing targeted small-molecule therapies for central nervous system disorders. The company uses a living human brain cell platform built from induced pluripotent stem cell-derived neurons to identify and optimize therapeutics aimed at neuroplasticity, neurogenesis, and neuroinflammation pathways. Its lead program, 4MT2001, is a selective glycogen synthase kinase 3 beta inhibitor being developed as a potentially safer and more effective alternative to lithium for bipolar disorder. The pipeline also includes programs for agitation in Alzheimer's disease and broader neurodegenerative conditions. The company appears to have previously operated under the name 4M Biotech before focusing its current business on CNS therapeutics as 4M Therapeutics.